Product Description
IRL942 and IRL1009 stem from IRLAB's P001 research program and are derived from the proprietary research platform ISP. IRL942 and IRL1009 are intended for treatment of mental and cognitive decline as well as declining motor skills linked to neurodegenerative diseases and ageing. (Sourced from: https://www.prnewswire.com/news-releases/irlabs-drug-candidates-irl942-and-irl1009-have-been-granted-patents-in-the-us-and-europe-300952695.html)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IRLAB
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Neurocognitive Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/06/2019 |
News Article |
IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe |